Skip to main content

Philips and World Stroke Organization partner to improve access to high-quality stroke care

A stroke patient rushed into the hospital

October 10, 2023

  • Two-year partnership focused on advocacy, education, and raising awareness of stroke as a global healthcare challenge
  • Philips’ leadership in the rapid end-to-end treatment of stroke helping to improve patient outcomes and increase the efficiency of treatment

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and the World Stroke Organization (WSO), the world’s only global non-governmental organization focused on stroke, today announced the signing of a two-year partnership aimed at improving access to high-quality stroke care. Building on their shared commitment to delivering improvements in stroke prevention, treatment, rehabilitation and support, Philips and WSO will leverage their respective strengths to elevate the public understanding of stroke as a global health issue, starting with joint initiatives on World Stroke Day 2023 (October 29) to build greater public awareness, which is fundamental to improving stroke patient outcomes. They will also work together to support the implementation of innovative treatment methods with the potential to transform the stroke care pathway, where reducing the time between symptom onset and effective treatment is critical to improving patient outcomes.

Announcing the partnership WSO President Prof Sheila Martins said, “WSO is committed to accelerating the global implementation of evidence-based treatment and care for stroke patients globally. We know what works and we know that it takes every part of the healthcare system, working together to bring quality care to every patient.”

“Both innovation and public awareness are essential to improve time-to-treatment and access to care for patients suffering a stroke,” said Dr. Atul Gupta, Chief Medical Officer of Image Guided Therapy at Philips. “Working closely with WSO, we can further shape the future of neurovascular interventions and help provide groundbreaking and effective high-quality care to patients so they can resume normal life after a stroke.”

Stroke is the second leading cause of death and the leading cause of disability worldwide, with around 12 million people experiencing a stroke each year, including 6.5 million people who die as a result. Those who do survive are often left with a complex range of communication, cognitive, physical, and emotional challenges for the rest of their life. To improve access to high-quality care that reduces the burden stroke places on individuals, and the financial and social impact it has on society, Philips and WSO will collaborate across a range of stroke-related areas. These include driving advocacy and policy based on the latest clinical research and treatment guidelines to inform government departments and healthcare providers about the latest developments in stroke treatment, and supporting community engagement.

Philips is a recognized leader in solutions that support the rapid treatment of stroke to minimize its impact on patients, including solutions for stroke monitoring and communication in ambulances, tele-stroke patient assessment, artificial intelligence (AI) supporting diagnostic imaging and analysis, image-guided therapy, and neurological and cardiac monitoring and assessment. The company also offers fully integrated angio suite systems designed to facilitate a stroke procedure called mechanical thrombectomy. During a thrombectomy, a specialized medical device is used to physically remove or break up the clot, restoring blood flow to the affected part of the brain. This quality-of-life-saving procedure is often performed to minimize damage to brain tissue and improve the chances of a patient’s recovery after a stroke.

For further information, please contact:

Joost Maltha 
Philips Global Press Office 
Tel: +31 6 10 55 8116  
Email: joost.maltha@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 71,500 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.